Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
G7 Explores AI Access Deal With U.S. Amid Anthropic Restrictions 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
REDWOOD CITY, Calif., Dec. 07, 2015 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on December 1, 2015, the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 129,600 shares of the company’s common stock with a per share exercise price of $24.12, the closing trading price on the grant date, and 64,800 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, VeltassaTM (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
